← Compound index
RESEARCH FAMILY / BDNF-MIMETICS

BDNF mimetics: GSB, GBK & GTSМиметики BDNF

Small synthetic peptides designed to mimic parts of brain-derived neurotrophic factor (BDNF), a protein involved in nerve-cell survival and signaling.

CognitionStress
Source linked

What the studies found

Animal research · 2016

Mimetics of brain-derived neurotrophic factor loops 1 and 4 are active in a model of ischemic stroke in rats

GSB-106 and GSB-214 reduced infarct volume by approximately 66% and 28%, respectively, in this experiment.

Study notes · methods, sources and limitations

Participants or model Rat middle cerebral artery occlusion plus HT-22 signaling assays

Important limitations

  • Animal results do not establish benefit or comparative potency in people. Effects are compound-specific and cannot be assigned to all BDNF mimetics.

Drug design, development and therapy · PMID 27843294 · Indexed abstract

Original source or citation ↗

Study results and tables ↗

Animal research · 2023

LC-MS/MS determination of GTS-201, a dipeptide mimetic of the brain-derived neurotrophic factor, and neurotransmitter metabolites with application to a pharmacokinetic study in rats.

After intraperitoneal GTS-201 in rats, reported elimination half-lives were about 19.5 minutes in plasma and 87.5 minutes in brain. Relative brain tissue availability was 2.9%; this is not human oral bioavailability.

Study notes · methods, sources and limitations

Participants or model Rat pharmacokinetics; plasma and brain LC-MS/MS

Important limitations

  • Preclinical findings do not establish human benefit or safety. Abstract only. Full methods and independent replication remain unconfirmed.

Journal of pharmaceutical and biomedical analysis · Indexed abstract

Original source or citation ↗

Study results and tables ↗

Animal research · 2022

Antidepressant-like Effects of BDNF and NGF Individual Loop Dipeptide Mimetics Depend on the Signal Transmission Patterns Associated with Trk

Study of multiple preparations

GSB-106 showed acute antidepressant-like activity; GSB-214 also became active with repeated administration. GTS-201 was inactive in this forced-swim comparison. Different signaling patterns did not yield interchangeable behavioral effects.

Study notes · methods, sources and limitations

Participants or model Rodent forced-swim tests; comparison with cell-signaling results

Important limitations

  • Behavioral proxies are not a clinical diagnosis or treatment outcome. Different schedules and models limit cross-compound comparisons.

Primary source linked above · Publication record

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About BDNF mimetics: GSB, GBK & GTS

Names in this research collection

GSB-104 · GSB-106 · GSB-120 · GSB-207 · GSB-214 · GBK-108 · GBK-201 · GTS-201 · TrkB

Research background

Small experimental mimetics of different BDNF loops, grouped for comparison of chemistry, signaling and behavioral results.

Compound class
Peptide research family
Research collection
Neuropeptide research · editorial grouping
Institutions in linked studies
See individual study records
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

No human treatment trial assessed for this family

Study methods

Member-specific studies; patents and archival leads identified separately

Independent replication

Independent replication not established by the records collected here

Source access

Primary abstracts, selected full texts, patents and explicit retrieval targets

Safety evidence

Cell and animal effects do not establish human safety; analogues may differ

Open a topic for the evidence assessment.

More findings, background and history
IDENTITY / MEMBER-SPECIFIC EVIDENCE

Inside this research family

Grouping supports navigation. It does not imply equivalent composition, mechanisms, effectiveness or safety.

Research objects, findings and source boundaries
MemberIdentityWhat the source supports
GSB-106Loop 4 dimer

Acute antidepressant-like activity in a rodent comparison; not a clinical antidepressant finding.

Antidepressant-like Effects of BDNF and NGF Individual Loop Dipeptide Mimetics Depend on the Signal Transmission Patterns Associated with Trk ↗

GSB-214Loop 1 dimer

Behavioral effects appeared with repeated administration in the comparison; not equivalent to GSB-106.

Antidepressant-like Effects of BDNF and NGF Individual Loop Dipeptide Mimetics Depend on the Signal Transmission Patterns Associated with Trk ↗

GTS-201Loop 2 dimer

Negative forced-swim result alongside separate rat brain-exposure measurements.

Antidepressant-like Effects of BDNF and NGF Individual Loop Dipeptide Mimetics Depend on the Signal Transmission Patterns Associated with Trk ↗

LC-MS/MS determination of GTS-201, a dipeptide mimetic of the brain-derived neurotrophic factor, and neurotransmitter metabolites with application to a pharmacokinetic study in rats. ↗

GSB-104 / GSB-120 / GBK-108Loop 4 patent examples

Sparse or conflicting assay descriptions; no shared clinical effect inferred.

Dipeptide mimetics of NGF and BDNF neurotrophins — US9683014B2 ↗

GSB-207 / GBK-201Loop 1 patent examples

Chemistry is documented; biological findings for these individual members have not been assessed.

Dipeptide mimetics of NGF and BDNF neurotrophins — US9683014B2 ↗

Interpretation and open questions

GSB-104 is described with both unfavorable and favorable survival results in patent prose; assay conditions and original tables need reconciliation.

Trk phosphorylation or dependence does not by itself demonstrate direct binding to the receptor.

Explore the Russian peptide research map ↗

Stroke research matrix ↗ — compare human stroke outcomes, experimental findings, safety and adjacent cerebral-ischemia research.

What remains unclear

The available experimental studies leave human benefit and safety uncertain.

No human intervention report has been identified among the linked records; unclassified archival leads may remain. Several publications can describe the same participants.

Browse original study records ↗
PATENT RESEARCH / COLLECTION UPDATED 7 NOVEMBER 2026

Patents and claimed inventions

These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.

2017 · US9683014B2 · Dipeptide mimetics of NGF and BDNF neurotrophins — US9683014B2Platform context · GSB-106 and imipramine reduced immobility; GBK-201 and GBK-108 increased it

Findings described in words

Experimental effects differ by candidate: some dimers were protective or antidepressant-like, while some monomers had unfavorable effects.

BDNF-model behavior
GSB-106 and imipramine reduced immobility; GBK-201 and GBK-108 increased itDifferent molecules; the unfavorable direction is retained
Candidate identity and viability
Some monomeric mimetics reduced neuronal viability; dimeric results were more favorableCandidate-specific findings, not a class-wide clinical effect
All reported results, comparisons and limitations →

Platform context. The title refers to NGF and BDNF mimetics, but the granted US claims specifically identify a Ser-Lys-based dimer. This is not a grant to every GK, GSB, GBK or GTS candidate.

A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.

Publication
US9683014B2 ↗ · 2017-06-20
Earliest priority / filing
2009-02-16 / 2014-08-15
Original applicant / assignee
Uchrezhdenie Rossiiskoi Akademii Meditsynskikh Nauk Nauchno-Issledovatelsky Institut Farmakologii Imeni Vvzakusova Ramn
Indexed status
Expired - Fee Related · checked 2026-11-06
Patent family
42561958 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Dipeptide mimetics of NGF and BDNF neurotrophins

Inventors: Sergey Borisovich Seredenin; Alexandrovna Tatyana GUDASHEVA.

US9683014B2 · US20110312895A1 · EP2397488B1 · CN102365294B · RU2410392C2 · WO2010093284A1

Original patent PDF ↗

Read source review →

Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →

03 / SOURCE RECORDS

Findings by study

Explore related research ↗

Animal research · 2016

Mimetics of brain-derived neurotrophic factor loops 1 and 4 are active in a model of ischemic stroke in rats

GSB-106 and GSB-214 reduced infarct volume by approximately 66% and 28%, respectively, in this experiment.

Study notes and original source
2016Animal / experimentalEnglish abstract

Mimetics of brain-derived neurotrophic factor loops 1 and 4 are active in a model of ischemic stroke in rats

Gudasheva TA, Povarnina P, Logvinov IO, Antipova TA, Seredenin SB · Drug design, development and therapy · PMID 27843294

GSB-106 and GSB-214 reduced infarct volume by approximately 66% and 28%, respectively, in this experiment.

Population / setting
Rat middle cerebral artery occlusion plus HT-22 signaling assays
Source reviewed
Indexed citation and abstract reviewed via Europe PMC / PubMed; full methods and risk of bias not comprehensively appraised.
Study limitations
  • Animal results do not establish benefit or comparative potency in people.
  • Effects are compound-specific and cannot be assigned to all BDNF mimetics.

Reviewed 2026-10-05.

Read the source ↗

Animal research · 2023

LC-MS/MS determination of GTS-201, a dipeptide mimetic of the brain-derived neurotrophic factor, and neurotransmitter metabolites with application to a pharmacokinetic study in rats.

After intraperitoneal GTS-201 in rats, reported elimination half-lives were about 19.5 minutes in plasma and 87.5 minutes in brain. Relative brain tissue availability was 2.9%; this is not human oral bioavailability.

Study notes and original source
2023Animal / experimentalEnglish abstract

LC-MS/MS determination of GTS-201, a dipeptide mimetic of the brain-derived neurotrophic factor, and neurotransmitter metabolites with application to a pharmacokinetic study in rats.

Markin PA, Moskaleva NE, Lebedeva SA, Kozin SV, Grigorevskikh EM, Kolik LG, Gudasheva TA, Appolonova SA · Journal of pharmaceutical and biomedical analysis

After intraperitoneal GTS-201 in rats, reported elimination half-lives were about 19.5 minutes in plasma and 87.5 minutes in brain. Relative brain tissue availability was 2.9%; this is not human oral bioavailability.

Population / setting
Rat pharmacokinetics; plasma and brain LC-MS/MS
Source reviewed
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
  • Preclinical findings do not establish human benefit or safety.
  • Abstract only. Full methods and independent replication remain unconfirmed.

Reviewed 2026-10-05.

Read the source ↗

Experiment described in a patent · 2017

Dipeptide mimetics of NGF and BDNF neurotrophins — US9683014B2

The description enumerates NGF and BDNF analogue series, but the granted US claims specifically identify a Ser-Lys-based dimer rather than every named candidate. GK-1/GK-2 and GSB-104 experiments remain preclinical and include identity or outcome ambiguities.

Study notes and original source
2017Patent / reported experimentsFull text available

Dipeptide mimetics of NGF and BDNF neurotrophins — US9683014B2

· Primary source linked above

The description enumerates NGF and BDNF analogue series, but the granted US claims specifically identify a Ser-Lys-based dimer rather than every named candidate. GK-1/GK-2 and GSB-104 experiments remain preclinical and include identity or outcome ambiguities.

Results and tables

Reported patent results

Findings described in words

Experimental effects differ by candidate: some dimers were protective or antidepressant-like, while some monomers had unfavorable effects.

Large NGF/BDNF-mimetic patent program with numerous cell and animal comparisons; the granted US claims are narrower than the experimental catalogue.

Population or model Patent chemistry and preclinical examples

Results · Selected neuronal-viability examples and final Porsolt comparisons, Figures 2.12–2.13.
MeasureResultComparison, timing and statistics
BDNF-model behaviorGSB-106 and imipramine reduced immobility; GBK-201 and GBK-108 increased itDifferent molecules; the unfavorable direction is retained
Candidate identity and viabilitySome monomeric mimetics reduced neuronal viability; dimeric results were more favorableCandidate-specific findings, not a class-wide clinical effect
Reporting conflictGSB-104 descriptions and GK-2f structure mapping require reconciliationNo single pooled efficacy percentage inferred from inconsistent examples

The title and broad description do not mean every experimental candidate is within the granted claims. Cell survival and behavioral proxies do not establish clinical antidepressant or neuroregenerative efficacy.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Patent chemistry and preclinical examples
Source reviewed
Selected original-source text checked; full methodological review pending.
Study limitations
  • Patent proposals are not established clinical uses.
  • Resolve code/structure ambiguities and assay-specific contradictions before interpreting activity.

Reviewed 2026-11-06.

Read the source ↗

Animal research · 2022

Antidepressant-like Effects of BDNF and NGF Individual Loop Dipeptide Mimetics Depend on the Signal Transmission Patterns Associated with Trk

GSB-106 showed acute antidepressant-like activity; GSB-214 also became active with repeated administration. GTS-201 was inactive in this forced-swim comparison. Different signaling patterns did not yield interchangeable behavioral effects.

Study notes and original source
2022Animal / experimentalFull text available

Antidepressant-like Effects of BDNF and NGF Individual Loop Dipeptide Mimetics Depend on the Signal Transmission Patterns Associated with Trk

· Primary source linked above

GSB-106 showed acute antidepressant-like activity; GSB-214 also became active with repeated administration. GTS-201 was inactive in this forced-swim comparison. Different signaling patterns did not yield interchangeable behavioral effects.

Population / setting
Rodent forced-swim tests; comparison with cell-signaling results
Source reviewed
Selected original-source text checked; full methodological review pending.
Study limitations
  • Behavioral proxies are not a clinical diagnosis or treatment outcome.
  • Different schedules and models limit cross-compound comparisons.

Reviewed 2026-10-05.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗